Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ECT

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: Comparative clinical and radiological studies on Fluor ProtectorR and DuraphatR.
    Active substance: SODIUM FLUORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 42342
    Study title: Comparative clinical and radiological studies on Fluor ProtectorR and DuraphatR.
    Active substance: SODIUM FLUORIDE
    Study summary document link (including results):
    View full study record
    Document reference: 42455
    Study title: Clinical effects and management of eucalyptus oil ingestion in infants and young children. Tibballs J, Med J Aust., 1995, 163:177-80.
    Active substance: Spike oil
    Study summary document link (including results):
    View full study record
    Document reference: 40224
    Study title: Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b. Journal of Clinical Oncology 1999;17(3):968-975 1999;(3):968-975.Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al. Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b. Journal of Clinical Oncology 1999;17(3):968-975 1999;(3):968-975.
    Active substance: TAMOXIFEN
    Study summary document link (including results):
    View full study record
    Document reference: 43353
    Study title: Open-label, 6-month, multicenter study in adolescents with schizophrenia. Subjects entered from RIS-USA-231 or RIS-SCH-302 or entered directly
    Active substance: RISPERIDONE
    Study summary document link (including results): RIS-USA-231_Interventional_Risperidone.xls
    View full study record
    Document reference: 35395
    Study title: Risperidone in adolsecents, effects on tolerability and quality of life, open pilot trial
    Active substance: RISPERIDONE
    Study summary document link (including results):
    View full study record
    Document reference: 35409
    Study title: Risperidone in the traztment of behavioural disturbances in mentally retarded children and adolescents: a double-blind placebo-controlled pilot trial.
    Active substance: RISPERIDONE
    Study summary document link (including results):
    View full study record
    Document reference: 35429
    Study title: Risperidone in the treatment of disruptive behavior disorders in children with intellectual limitations. One-year continuation study.
    Active substance: RISPERIDONE
    Study summary document link (including results): RIS-CAN-20_Interventional_Risperidone.xls
    View full study record
    Document reference: 35430
    Study title: Baydas B, Yavuz I, Uslu H, Dagsuyu IM, Ceylan I. Nonsurgical rapid maxillary expansion effects on craniofacial structures in young adult females. A bone scintigraphy study. Angle Orthod. 2006 Sep;76(5):759-67. Baydas B, Yavuz I, Uslu H, Dagsuyu IM, Ceylan I. Nonsurgical rapid maxillary expansion effects on craniofacial structures in young adult females. A bone scintigraphy study. Angle Orthod. 2006 Sep;76(5):759-67.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43370
    Study title: Fig LM, Shulkin BL. Scintigraphic detection of sinusitis. Eur J Nucl Med. 1988;14(11):552-4. Fig LM, Shulkin BL. Scintigraphic detection of sinusitis. Eur J Nucl Med. 1988;14(11):552-4.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43835
    Study title: Fischer-Brandies E, Seifert C. Bone scintigraphy: an aid in deciding on the extent of bone resection in malignant oral tumors. J Oral Maxillofac Surg. 1995 Jul;53(7):768-70. Fischer-Brandies E, Seifert C. Bone scintigraphy: an aid in deciding on the extent of bone resection in malignant oral tumors. J Oral Maxillofac Surg. 1995 Jul;53(7):768-70.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43595
    Study title: Myrtol standardized in the treatment of acute and chronic respiratory infections in children. A multicenter post-marketing surveillance study. Sengespeik HC et al., Arzneimittelforschung, 1998: 990-4.
    Active substance: Spike oil
    Study summary document link (including results):
    View full study record
    Document reference: 40225
    Study title: Retrospective survey for documentation of appllication and dosage of Spigelon (tablets) in children < 12 years of age [Bef-026]
    Active substance: Spigelon
    Study summary document link (including results):
    View full study record
    Document reference: 40245
    Study title: Adverse effects of herbal drugs in dermatology, Ernst, E., Br.J.Dermatol. 2000; 143 (5): 923-929
    Active substance: Spike oil
    Study summary document link (including results):
    View full study record
    Document reference: 40215
    Study title: Adverse effects of herbal drugs in dermatology, Ernst, E., Br.J.Dermatol. 2000; 143 (5): 923-929 Camphor ingestion, Gibson, D.E., Am. J. Emerg. Med. 1989; 7 (1): 41-43
    Active substance: Spike oil, Eucalyptus oil, Turpentine oil, Camphor
    Study summary document link (including results):
    View full study record
    Document reference: 40239
    Study title: Aglietti P, Zaccherotti G, De Biase P, Taddei I. A comparison between medial meniscus repair, partial meniscectomy, and normal meniscus in anterior cruciate ligament reconstructed knees. Clin Orthop Relat Res. 1994 Oct;(307):165-73. Aglietti P, Zaccherotti G, De Biase P, Taddei I. A comparison between medial meniscus repair, partial meniscectomy, and normal meniscus in anterior cruciate ligament reconstructed knees. Clin Orthop Relat Res. 1994 Oct;(307):165-73.
    Active substance: TECHNETIUM (99mTc) MEDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 43613
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 03 15:20:05 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA